Clostridium difficile colitis.

Clostridium difficile, the agent that causes pseudomembranous colitis associated with antibiotic therapy, has been identified in recent years as a common nosocomial pathogen. First described in 1935 by Hall and O'Toole, this gram-positive anaerobic bacillus was named “the difficult clostridium” because it resisted early attempts at isolation and grew very slowly in culture1. Although the organism released potent toxins in broth culture, the fact that it was found in stool specimens from healthy neonates led to its classification as a commensal. C. difficile subsequently passed into obscurity. In the 1960s and 1970s antibiotic-associated pseudomembranous colitis became a major clinical . . .

[1]  R Sedivy,et al.  Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.

[2]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[3]  A. Glatt,et al.  Clostridium difficile infection associated with antineoplastic chemotherapy: a review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Pothoulakis,et al.  Clostridium difficile-associated diarrhea and colitis: pathogenesis and therapy. , 1993, International journal of antimicrobial agents.

[5]  Esther Jacobowitz Israel,et al.  Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. , 1992, The Journal of clinical investigation.

[6]  L. Peterson,et al.  Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole , 1992, Annals of Internal Medicine.

[7]  G. Doern,et al.  Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays , 1992, Journal of Clinical Microbiology.

[8]  K.,et al.  Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A , 1992, Journal of clinical microbiology.

[9]  N. Schupf,et al.  Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. , 1992, Infection control and hospital epidemiology.

[10]  D. Conwell,et al.  Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease , 1991, Journal of clinical microbiology.

[11]  T. Wilkins,et al.  Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase , 1991, Journal of clinical microbiology.

[12]  G. Triadafilopoulos,et al.  Acute abdomen as the first presentation of pseudomembranous colitis. , 1991, Gastroenterology.

[13]  C. Pothoulakis,et al.  Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. , 1991, The Journal of clinical investigation.

[14]  W. Stamm,et al.  Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients , 1991, Infection and immunity.

[15]  C. Pothoulakis,et al.  Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. , 1991, The Journal of pediatrics.

[16]  L. Peterson,et al.  Nosocomial Clostridium difficile colonisation and disease , 1990, The Lancet.

[17]  C. Pothoulakis,et al.  Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. , 1990, Cellular immunology.

[18]  L. Peterson,et al.  Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. , 1990, The American journal of medicine.

[19]  S. Borriello The influence of the normal flora on Clostridium difficile colonisation of the gut. , 1990, Annals of medicine.

[20]  C. Surawicz,et al.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. , 1989, The American journal of gastroenterology.

[21]  J. Rask-Madsen,et al.  BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.

[22]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.

[23]  C. Pothoulakis,et al.  Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. , 1988, The Journal of clinical investigation.

[24]  C. Pothoulakis,et al.  Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. , 1988, The Journal of clinical investigation.

[25]  K. Wilson,et al.  Acquisition of Clostridium difficile from the hospital environment. , 1988, American journal of epidemiology.

[26]  D. Weaver,et al.  Surgical management of pseudomembranous colitis. , 1988, The American surgeon.

[27]  D. Kleinfeld,et al.  Parenteral therapy for antibiotic-associated pseudomembranous colitis. , 1988, The Journal of infectious diseases.

[28]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[29]  C. Kelly,et al.  An epidemic of pseudomembranous colitis: importance of person to person spread. , 1987, Gut.

[30]  M. O'brien,et al.  Differential effects of Clostridium difficile toxins A and B on rabbit ileum. , 1987, Gastroenterology.

[31]  J. Silva,et al.  Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. , 1987, Journal of clinical gastroenterology.

[32]  R. Bolton,et al.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. , 1986, Gut.

[33]  J. Bartlett,et al.  IS CLOSTRIDIUM DIFFICILE ENDEMIC IN CHRONIC-CARE FACILITIES? , 1986, The Lancet.

[34]  G. Young,et al.  Antibiotic-associated colitis: why do patients relapse? , 1986, Gastroenterology.

[35]  D. Gordon,et al.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.

[36]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[37]  R. Yolken,et al.  Serum antibody response to toxins A and B of Clostridium difficile. , 1983, The Journal of infectious diseases.

[38]  I. Hill,et al.  Epidemiology of Clostridium difficile in infants. , 1982, The Journal of infectious diseases.

[39]  F. Tedesco,et al.  Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. , 1982, Gastroenterology.

[40]  Tedesco Fj Treatment of recurrent antibiotic-associated pseudomembranous colitis. , 1982 .

[41]  J. Silva,et al.  Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. , 1981, The American journal of medicine.

[42]  M. Keighley,et al.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. , 1978, British medical journal.

[43]  Kreutzer Ew,et al.  Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. , 1978, The Johns Hopkins medical journal.

[44]  F. Tedesco,et al.  ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.

[45]  A. Price,et al.  CLOSTRIDIUM DIFFICILE AND THE ÆTIOLOGY OF PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.

[46]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[47]  J. Parry,et al.  Undescribed toxin in pseudomembranous colitis. , 1977, British medical journal.

[48]  R. Barton,et al.  Clindamycin-associated colitis. A prospective study. , 1974, Annals of internal medicine.

[49]  I. C. Hall,et al.  INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS , 1935 .

[50]  C. Pothoulakis,et al.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. , 1992, Gastroenterology.

[51]  S. Tabaqchali,et al.  Epidemiologic markers of Clostridium difficile. , 1990, Reviews of infectious diseases.

[52]  L. Briceland,et al.  Multidisciplinary cost-containment program promoting oral metronidazole for treatment of antibiotic-associated colitis. , 1988, American journal of hospital pharmacy.